中剂量依托泊苷联合粒细胞集落刺激因子动员恶性淋巴瘤的外周血造血干/祖细胞

 目的　观察中剂量依托泊苷（VP16）和粒细胞集落刺激因子（G-CSF）在恶性淋巴瘤患者动员采集自体外周血造血干／祖细胞的有效性和安全性。方法　31例恶性淋巴瘤患者（非霍奇金淋巴瘤30例，霍奇金淋巴瘤1例），VP16 1.2 g／m2分3 d静脉滴注，外周血白细胞降至最低点时给予G-CSF每天5 μg／kg，分2次，皮下注射，直至采集结束。结果　VP16应用后12 d（10～15 d）开始采集外周血造血干／祖细胞，获得单个核细胞（MNC）7.8×108／kg（5.2～11.3）×108／kg]，CD+34细胞7.2×106／kg （5.3～13.1）×106／kg]。18例患者采集1次，13例采集2次。所有患者移植后均恢复造血，外周血粒细胞>0.5×109／L的中位时间为12 d（9～18 d），血小板>20×109／L的中位时间为14 d（10～21 d）。患者无严重不良反应。结论　中剂量VP16和G-CSF 动员恶性淋巴瘤患者外周血干／祖细胞有效、安全，可获得满意的动员采集效果。

Etoposide as moderate dose with granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem/progenitor cells in patients with malignant lymphoma

Objective To explore the efficacy and safety of moderate-dose of etoposide （VP16） with granulocyte-colony-stimulating factor （G-CSF） for mobilization of peripheral blood stem/progenitor cells. Methods VP16 at 1.2 g/m^2 was injected intravenously by six divided doses via a central vein, 2 times every 12 hours for 3 days in 31 patients with malignant lymphoma （30 non-Hodgkin lymphoma and 1 Hodgkin lymphoma）. All patients received G-CSF 5 /μg/kg were given twice daily subcutaneously from the day of the nadir of white blood cell （WBC） till the day before the last APBSC harvest. Results The mean time for the collection of stem cell was 12 days （10-15） following etoposide chemotherapy. The mean number of mononuclear cell （MNC） and CD;4 cells in collection were 7.8xl0^8/kg （5.2-11.3x10^8） and 7.2xl0^6/kg （5.3- 13.1 x10^6）, respectively. 18 patients completed collection with a single apheresis, and 13 patients underwent twice. All patients were recovered for haematopoiesis in following APBSCT. Median （range） time for the recovery of absolute neutrophil count （ANC）〉0.5x10^9/L and platelet〉20x10^9/L were＋12 （＋9-＋18） days and ＋ 14 （＋10-＋21） days respectively. Slight adverse events coursed by the regimen could be tolerated. Conclusion VPl6 at moderate dose with G-CSF is an effective and safe mobilizing regimen for autologous peripheral blood stem/progenitor cells in patients with malignant lymphoma. It was suggested to use extensively.